Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAPITAL phase II study of capivasertib in relapsed or refractory B-cell non-Hodgkin lymphoma
2021-000870-27Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of capivasertib in mature B-cell lymphoma and follicular lymphoma (FL), sponsored by AstraZeneca. Primary endpoint: Objective response rate. Started May 2021; status: completed.
02
Drugs
capivasertib
03
Conditions
mature B-cell lymphomafollicular lymphoma (FL)
Beyond the preview
Go deeper on 2021-000870-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000870-27.